SRR658977
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.437
- KRAS_SIGNALING_DN+0.426
- MYOGENESIS+0.356
- ANGIOGENESIS+0.327
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.237
- APICAL_SURFACE+0.221
- ESTROGEN_RESPONSE_LATE+0.183
- SPERMATOGENESIS+0.178
- KRAS_SIGNALING_UP+0.132
- HEDGEHOG_SIGNALING+0.114
Top 10 suppressed
- MYC_TARGETS_V1-0.655
- OXIDATIVE_PHOSPHORYLATION-0.624
- UNFOLDED_PROTEIN_RESPONSE-0.550
- DNA_REPAIR-0.523
- E2F_TARGETS-0.517
- MYC_TARGETS_V2-0.499
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.465
- MTORC1_SIGNALING-0.461
- G2M_CHECKPOINT-0.437
- PROTEIN_SECRETION-0.433
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1316624 | GTEX | — | 0.958 |
| 2 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.958 |
| 3 | BS_CZ82ANWP | DNET | — | 0.953 |
| 4 | SRR1451964 | GTEX | — | 0.950 |
| 5 | SRR1474886 | GTEX | — | 0.948 |
| 6 | SRR1353285 | GTEX | — | 0.947 |
| 7 | SRR1394713 | GTEX | — | 0.947 |
| 8 | SRR1487825 | GTEX | — | 0.945 |
| 9 | SRR1397073 | GTEX | — | 0.944 |
| 10 | SRR1361674 | GTEX | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.437 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.426 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.356 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.327 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.237 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.221 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.183 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.178 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.132 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.114 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.098 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.093 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.077 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.015 | Binimetinib | — uncovered |